Vaxcyte Inc. Common Stock vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42 (market cap $3.80B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.8× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 96 Days on average.
| PCVX | VNQI | |
|---|---|---|
Market Cap | $10.51B | $3.80B |
Volume | 2,644,694 | 274,816 |
Sector | Health | — |
52-Week High | $73.82 | $50.76 |
52-Week Low | $40.32 | $41.81 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNQI trades at $42.04, up 0.14% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF focuses on international real estate outside the U.S., offering diversification across more than 30 countries and a competitive expense ratio of 0.12%. Recent news highlights a significant drop in short interest in September 2026, suggesting reduced bearish speculation, while comparisons with peers emphasize its higher dividend yield.
The outlook remains cautious due to global real estate market volatility and bearish technicals, though reduced short interest and international exposure present opportunities for yield-seeking investors. Risks include currency fluctuations and economic downturns in foreign markets, requiring careful monitoring of macroeconomic trends for potential recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →